Press "esc" to clear
Go to Advanced Search

Showing results

4150 of 3009
apostolia_tsimberidou.jpg
  • Embargo expired:
    2-Jun-2018 7:30 AM EDT

Article ID: 695493

Long-Term IMPACT Data Find Improved Survival When Targeted Therapies Matched to Tumor-Specific Gene Mutations

University of Texas M. D. Anderson Cancer Center

Matching targeted therapies to tumor-specific gene mutations across tumor types improved progression-free survival (PFS) and overall survival (OS) in patients with advanced disease relative to those receiving non-matched treatment (NMT), according to research from The University of Texas MD Anderson Cancer Center. The researchers also found that receiving matched targeted therapy (MTT) was an independent factor for predicting longer OS.

Released:
1-Jun-2018 4:45 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
FenstermakerandCiesielskiLab2012-08-2133.jpg

Article ID: 695497

Interim Results from Clinical Trial of Immunotherapy for Glioblastoma Show Significant Clinical Benefit

Roswell Park Comprehensive Cancer Center

Presenting new data at ASCO 2018, collaborators from Roswell Park Comprehensive Cancer Center, the Cleveland Clinic and MimiVax LLC report that the combination of SurVaxM plus standard therapy for patients with glioblastoma appears to be safe, effective and worthy of further evaluation.

Released:
1-Jun-2018 5:05 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment

Article ID: 695477

Sidney Kimmel Cancer Center Scientists to Present on Uveal Melanoma, Biden Cancer Initiative and More at ASCO Annual Meeting

Thomas Jefferson University

Scientists from the Sidney Kimmel Cancer Center (SKCC) at Jefferson Health will be presenting research and leading discussions on various topics, including metastatic uveal melanoma, genetic counseling in men, immunotherapy in early stage lung cancer and solid tumors, quality of life among patients receiving treatment for T cell lymphoma and updates on the Cancer Moonshot during the Biden Cancer Initiative Colloquium at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 1-5 in Chicago.

Released:
1-Jun-2018 2:40 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
  • Embargo expired:
    1-Jun-2018 2:00 PM EDT

Article ID: 695436

Analysis: Survival Benefit for African-Americans with Advanced Prostate Cancer

Duke Health

Contrary to current perceptions, certain African-American men with advanced prostate cancer have as good a chance of survival as white men and might actually have a small advantage, according to a new analysis of more than 8,000 patients who participated in clinical trials.

Released:
1-Jun-2018 2:00 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
  • Embargo expired:
    1-Jun-2018 2:00 PM EDT

Article ID: 695437

Black Patients Show Stronger Response to Hormone Therapy for Prostate Cancer

Duke Health

African-American men with advanced prostate cancer might be more responsive than white men to an anti-androgen drug and steroids, according to a study led by Duke Cancer Institute researchers.

Released:
1-Jun-2018 2:00 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment

Article ID: 695459

Cleveland Clinic Cancer Center Experts Present Data at 2018 ASCO Annual Meeting

Cleveland Clinic

At the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, researchers from Cleveland Clinic Cancer Center will present data from several new studies, including a prospective clinical trial examining non-small cell lung cancer cells’ response to immunotherapy; research on germline testing for melanoma; and interim results from a study testing a vaccine for glioblastoma.

Released:
1-Jun-2018 12:05 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment

Article ID: 695362

Beyond BRCA: Examining Links between Breast Cancer, Second Primary Cancer and Inherited Genetic Mutations

Perelman School of Medicine at the University of Pennsylvania

Rates of inherited mutations in genes other than BRCA1/2 are twice as high in breast cancer patients who have had a second primary cancer – including, in some cases, different types of breast cancer – compared to patients who have only had a single breast cancer.

Released:
31-May-2018 9:55 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
5-3-2018JohnsHopkinsResearchersatPediatricAcademicSocietiesMeeting2018.jpg

Article ID: 695250

TIP SHEET: Johns Hopkins Researchers Well Represented at ASCO 2018 Annual Meeting

Johns Hopkins Medicine

The American Society of Clinical Oncology Annual Meeting brings together more than 32,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field

Released:
30-May-2018 9:00 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment

Article ID: 695192

Best Podium and Poster Presentations Awarded at ISPOR 2018

ISPOR—The Professional Society for Health Economics and Outcomes Research

ISPOR, the professional society for health economics and outcomes research, announced the Best Podium and Poster Research Presentation awardees for its ISPOR 2018 conference held in Baltimore, MD, USA on May 19-23, 2018.

Released:
29-May-2018 10:40 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
Pryma.Daniel_WhiteCoat.jpg

Article ID: 695188

Penn-led Trial Shows AZEDRA Can Be Effective, Safe for Treatment of Rare Neuroendocrine Tumors

Perelman School of Medicine at the University of Pennsylvania

A radiotherapy drug that treats the rare neuroendocrine cancers pheochromocytoma and paraganglioma can be both effective and safe for patients, according to the findings of a multi-center trial led by researchers in the Abramson Cancer Center of the University of Pennsylvania.

Released:
29-May-2018 9:45 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment

Showing results

4150 of 3009





Chat now!